PRODUCT
Summary
Non-lytic: Acts as a long lasting fusion protein which only binds to the receptor. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC).
APPLICATION
Application Note
Measured by its ability to inhibit IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells.
PROPERTIES
Form
Lyophilized powder
Buffer
Reconstitute with 0.2μm-filtered PBS to 100 μg/ml. Lyophilized from 0.2μm-filtered PBS.
Preservative
No preservative
Storage
Store at -20ºC or below. After reconstitution, keep as concentrated solution. Aliquot and avoid freeze-thaw cycles.
Region/Sequence
The extracellular domain of human CD152 [CTLA-4] (a.a. 37-160) is fused to the N-terminus of the Fc region of a mutant human IgG1.
Expression System
CHO cells
Purity
??98% by SDS-PAGE.
Endotoxin
< 0.06 EU/μg
Conjugation
Unconjugated
Note
For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET
Synonyms
cytotoxic T-lymphocyte associated protein 4 , ALPS5 , CD , CD152 , CELIAC3 , CTLA-4 , GRD4 , GSE , IDDM12
Database
Research Area
REFERENCE
There are currently no references for Human CTLA4 protein, mutant human IgG1 Fc tag (active) (GTX65744-pro). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for Human CTLA4 protein, mutant human IgG1 Fc tag (active) (GTX65744-pro). Be the first to share your experience with this product.